JP2010090168A5 - - Google Patents

Download PDF

Info

Publication number
JP2010090168A5
JP2010090168A5 JP2010007969A JP2010007969A JP2010090168A5 JP 2010090168 A5 JP2010090168 A5 JP 2010090168A5 JP 2010007969 A JP2010007969 A JP 2010007969A JP 2010007969 A JP2010007969 A JP 2010007969A JP 2010090168 A5 JP2010090168 A5 JP 2010090168A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
dissolution test
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010007969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010090168A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2010007969A priority Critical patent/JP2010090168A/ja
Priority claimed from JP2010007969A external-priority patent/JP2010090168A/ja
Publication of JP2010090168A publication Critical patent/JP2010090168A/ja
Publication of JP2010090168A5 publication Critical patent/JP2010090168A5/ja
Pending legal-status Critical Current

Links

JP2010007969A 2007-03-29 2010-01-18 医薬組成物 Pending JP2010090168A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010007969A JP2010090168A (ja) 2007-03-29 2010-01-18 医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007087327 2007-03-29
JP2010007969A JP2010090168A (ja) 2007-03-29 2010-01-18 医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009510780A Division JP4463875B2 (ja) 2007-03-29 2008-03-28 医薬組成物

Publications (2)

Publication Number Publication Date
JP2010090168A JP2010090168A (ja) 2010-04-22
JP2010090168A5 true JP2010090168A5 (https=) 2011-03-10

Family

ID=39875378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009510780A Active JP4463875B2 (ja) 2007-03-29 2008-03-28 医薬組成物
JP2010007969A Pending JP2010090168A (ja) 2007-03-29 2010-01-18 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009510780A Active JP4463875B2 (ja) 2007-03-29 2008-03-28 医薬組成物

Country Status (28)

Country Link
US (3) US20100081685A1 (https=)
EP (1) EP2140867B2 (https=)
JP (2) JP4463875B2 (https=)
KR (1) KR101424843B1 (https=)
CN (2) CN101652139A (https=)
AU (1) AU2008241982B2 (https=)
BR (1) BRPI0809205B8 (https=)
CA (1) CA2680039C (https=)
CO (1) CO6220955A2 (https=)
CY (1) CY1119377T1 (https=)
DK (1) DK2140867T4 (https=)
ES (1) ES2644803T5 (https=)
FI (1) FI2140867T4 (https=)
HR (1) HRP20171384T4 (https=)
HU (2) HUE035990T2 (https=)
IL (2) IL200790A (https=)
LT (2) LT2140867T (https=)
MX (2) MX351987B (https=)
MY (1) MY149356A (https=)
NO (1) NO20093008L (https=)
NZ (2) NZ597109A (https=)
PL (1) PL2140867T5 (https=)
PT (1) PT2140867T (https=)
SG (1) SG179497A1 (https=)
SI (1) SI2140867T2 (https=)
TW (1) TWI409064B (https=)
WO (1) WO2008129846A1 (https=)
ZA (2) ZA200906182B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179497A1 (en) 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
JPWO2010071164A1 (ja) * 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第X因子(FXa)阻害剤
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AU2010242308A1 (en) * 2009-04-30 2011-12-01 Takeda Pharmaceutical Company Limited Solid preparation
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
ES2706880T3 (es) * 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
JP5870023B2 (ja) * 2010-02-22 2016-02-24 第一三共株式会社 経口用徐放性固形製剤
JP5692873B2 (ja) * 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013026553A1 (en) 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
JP6227352B2 (ja) * 2012-09-27 2017-11-08 株式会社三和化学研究所 アナグリプチン又はその塩を含有する固形製剤
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
TW201521794A (zh) * 2013-11-12 2015-06-16 Daiichi Sankyo Co Ltd 錠劑
US20170022220A1 (en) * 2014-02-25 2017-01-26 Daiichi Sankyo Company, Limited High-purity crystals of active blood coagulation factor x (fxa) inhibitor
US20170368037A1 (en) * 2014-12-26 2017-12-28 Daiichi Sankyo Company, Limited Pharmaceutical composition for promotion of fibrinolysis
CN107405342B (zh) * 2015-12-24 2021-05-14 江苏恒瑞医药股份有限公司 一种含有二胺衍生物或其盐的固体药物组合物
US20190364946A1 (en) * 2016-03-16 2019-12-05 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
TWI812602B (zh) 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
KR102222774B1 (ko) * 2018-07-27 2021-03-04 보령제약 주식회사 에독사반을 포함하는 약학적 제제 및 이의 제조방법
KR20200079957A (ko) 2018-12-26 2020-07-06 한국콜마주식회사 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법
KR102514961B1 (ko) 2019-03-05 2023-03-28 주식회사 파마코스텍 에독사반 벤젠술폰산염 1 수화물 결정형 및 그 제조방법
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
KR20210048632A (ko) 2019-10-23 2021-05-04 한미약품 주식회사 에독사반 유리 염기 함유 제약 조성물
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
KR102090912B1 (ko) 2019-12-18 2020-03-18 유니셀랩 주식회사 신규한 결정형 형태의 에독사반 및 이의 제조방법
EP3838267A1 (en) 2019-12-19 2021-06-23 Biohorm, S.L. Edoxaban tablets
KR102513519B1 (ko) 2020-06-08 2023-03-23 주식회사 파마코스텍 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법
KR102222784B1 (ko) 2020-09-17 2021-03-04 유니셀랩 주식회사 신규한 에독사반 헤미에틸렌다이설퍼닉산 염 일수화물
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
JP2022113667A (ja) * 2021-01-25 2022-08-04 全星薬品工業株式会社 エドキサバン含有医薬組成物
JP2023056113A (ja) * 2021-10-07 2023-04-19 日医工株式会社 エドキサバン含有医薬組成物
KR102518204B1 (ko) 2022-02-18 2023-04-05 주식회사 엔비피헬스케어 신규한 에독사반 프로필렌글리콜 용매화물
EP4629970A1 (en) 2022-12-09 2025-10-15 Synthon B.V. Formulation comprising edoxaban and preparation thereof
JP7352248B1 (ja) * 2023-03-27 2023-09-28 学校法人藤田学園 抗がん剤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5149855A (en) 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
US5055600A (en) 1990-04-24 1991-10-08 Rockwell International Corporation Glycidyl azide polymer (gap) synthesis by molten salt method
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
US5677469A (en) 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
JPH09309829A (ja) * 1996-05-22 1997-12-02 Taiyo Yakuhin Kogyo Kk ニトレンジピン含有経口投与製剤およびその製造法
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JPH11180899A (ja) 1997-12-15 1999-07-06 Mitsui Chem Inc 活性メチレンアルキル化化合物の製造法
JP3680203B2 (ja) 1999-06-01 2005-08-10 東洋化成工業株式会社 4−アセチルアミノベンゼンスルホニルアジドの製造方法
JP2001151724A (ja) 1999-11-19 2001-06-05 Kuraray Co Ltd 光学活性な2,2,4−トリメチル−3−シクロヘキセンカルボン酸の製造方法
JP4044709B2 (ja) 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
RU2271805C2 (ru) 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US20020160048A1 (en) * 2001-02-15 2002-10-31 Karoline Bechtold-Peters Medical formulation containing a muscarinic agonist
DE10106971A1 (de) 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Arzneimittelformulierung die einen muskarinischen Agonisten enthält
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
JP4128138B2 (ja) 2001-06-20 2008-07-30 第一三共株式会社 ジアミン誘導体
KR100908418B1 (ko) * 2001-06-20 2009-07-21 액티버스 파마 컴퍼니 리미티드 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP3939601B2 (ja) * 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
PL368402A1 (en) 2001-08-09 2005-03-21 Daiichi Pharmaceutical Co, Ltd. Diamine derivatives
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
JP4109288B2 (ja) 2002-12-25 2008-07-02 第一三共株式会社 ジアミン誘導体
CA2521325C (en) * 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
CN102166212A (zh) 2003-06-17 2011-08-31 协和发酵麒麟株式会社 使盐酸贝尼地平从片剂中迅速溶出的方法
JP4606258B2 (ja) * 2003-06-17 2011-01-05 協和発酵キリン株式会社 塩酸ベニジピン含有医薬組成物
CA2545730C (en) 2003-11-12 2014-07-08 Daiichi Pharmaceutical Co., Ltd. Process for producing thiazole derivative
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
BRPI0615775B1 (pt) 2005-09-16 2021-08-10 Daiichi Sankyo Company, Limited Processos para a produção de compostos derivados de diamida oticamente ativos
JP4703333B2 (ja) 2005-09-26 2011-06-15 エヌ・ティ・ティ・ソフトウェア株式会社 電子メール処理プログラム
SG179497A1 (en) 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
TW200909437A (en) 2007-06-21 2009-03-01 Daiichi Sankyo Co Ltd Process for the preparation of diamine-derivatives
BRPI0922434A2 (pt) 2008-12-12 2015-12-15 Daiichi Sankyo Co Ltd processo para produzir ácido carboxílico opticamente ativo
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
JPWO2010071164A1 (ja) 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第X因子(FXa)阻害剤
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
WO2010131663A1 (ja) 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
TW201102064A (en) 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
JP2011051672A (ja) 2009-08-31 2011-03-17 Ihi Corp ラック棚及びラック棚の組立て方法
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment

Similar Documents

Publication Publication Date Title
JP2010090168A5 (https=)
JP6561105B2 (ja) 過活動膀胱の治療のための医薬製剤
JP2009545560A5 (https=)
RU2012101649A (ru) Фармацевтическая композиция, обладающая улучшенной растворимостью
JP2020059755A5 (https=)
NZ597109A (en) Tablet composition having favorable dissolution property useful as an anticoagulant
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
JP2011519967A5 (https=)
JP2014532638A5 (https=)
JP2015511953A5 (https=)
CA2462482A1 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
RU2012131158A (ru) Фармацевтическая композиция с контролируемым высвобождением лекарственного средства
ES2364538T3 (es) Combinación farmacéutica de alisquireno y valsartán.
TR201818761T4 (tr) 4-amino-5-floro-3-[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]-1h-kinolin-2-on laktat monohidrat içeren farmasötik bileşimler.
AU2015349896B2 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
CN104114163A (zh) 治疗心血管疾病的方法
JP2019529570A (ja) ミドドリンの組成物およびその使用方法
JP2011502140A (ja) トルテロジンの制御放出型医薬組成物
CN1271281A (zh) 控释活性化合物的药物制剂
JP2011516544A5 (https=)
CN105769773B (zh) 洛索洛芬钠缓释微丸
RU2011110756A (ru) Фармацевтическая композиция в виде разовой пероральной дозы, содержащая леводопу, карбидопу и энтакапон, или их соли
JP2012140335A (ja) 不快味マスキング粒子及びこれを含有する経口製剤
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина